GENTAMICIN SULFATE Ophthalmic Solution, USP 0.3%

Manufacturer
Rebel Distributors Corp
Effective date
2010-09-27
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:10:35

Label at a glance#

ProductGENTAMICIN SULFATE
Active ingredientgentamicin sulfate
Label structure11 sections

Indications and uses

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus...

Dosage and administration

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Sterile

DESCRIPTION

DESCRIPTION SECTION

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is a sterile, topical anti-infective agent for ophthalmic use. The active ingredient, gentamicin sulfate, is a water-soluble antibiotic of the aminoglycoside group.

Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as a white to buff powder and is soluble in water but insoluble in alcohol. The structural formula is as follows:

Chemical Structure
Chemical Structure

Each mL contains: Active: gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. Preservative: benzalkonium chloride. Inactives: edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide to adjust the pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

SPL UNCLASSIFIED SECTION

Microbiology: Gentamicin sulfate is active in vitro against many strains of the following micro-organisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is contraindicated in patients with known hypersensitivity to any of the components.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE.

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

PRECAUTIONS SECTION

General:

GENERAL PRECAUTIONS SECTION

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible microorganisms, including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy:

PREGNANCY SECTION

SPL UNCLASSIFIED SECTION

Pregnancy Category C: Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

PEDIATRIC USE SECTION

Safety and effectiveness in neonates have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia. Other reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

HOW SUPPLIED SECTION

GENTAMICIN SULFATE OPHTHALMIC SOLUTION, USP 0.3% is supplied sterile in white opaque LDPE plastic bottles and tips with white high impact polystyrene (HIPS) caps as follows:

  •       5 mL in 10 mL bottle – NDC 60758-188-05

Note: Store at or below 25°C (77°F). Avoid exposure to excessive heat (40°C/104°F or above).

Rx only

Rev January 2003

© 2004 PACIFIC PHARMA
Irvine, CA 92612 U.S.A.
6622X
71759PY10P

Repackaged by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Gentamicin Sulf Ophth 0.3%Gentamicin Sulf Ophth 0.3%

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310467gentamicin sulfate 0.3 % Ophthalmic SolutionPSN1
310467gentamicin 3 MG/ML Ophthalmic SolutionSCD1
310467gentamicin (as gentamicin sulfate) 0.3 % Ophthalmic SolutionSY1
310467gentamicin sulfate 3 MG/ML Ophthalmic SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
GENTAMICIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
3b7b3a7a-635f-32a3-0c6c-7ad028e3de91Product name220250107
43025f0d-698c-68da-cec9-ea4261a7ef7aProduct name220250107
d3946667-8212-d1f2-67e1-5643a329bb56Product name220200403
4ce5dce5-e8a7-e4f6-0059-b527e4307477Product name220190501
48b05f5d-d2fc-45ab-76e8-3cb5bd44890dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21695-187-05GENTAMICIN SULFATE5 mL in 1 BOTTLE, DROPPERSOLUTION51
21695-187-15GENTAMICIN SULFATE15 mL in 1 BOTTLE, DROPPERSOLUTION151

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
21695-187GENTAMICIN SULFATE SOLUTION [REBEL DISTRIBUTORS CORP]1Legacy NDC, 2 package rows20101126_d7a27e38-0553-4d4b-8438-fed235e9b989.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
21695-187-05ML - Milliliter21695-187c9328ed0-4711-4732-a4e2-d0e11c2a4c4712012-07-24
21695-187-15ML - Milliliter21695-1875e7a5432-44af-4f31-94bf-c92570fefdbf12012-07-24
60758-188-05ML - Milliliter60758-188d155d9ac-d56c-4938-a7d3-39ee324dd1f512012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
gentamicin sulfateACTIVE INGREDIENT8X7386QRLV1
gentamicinACTIVE MOIETYT6Z9V48IKG1
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W71
edetate disodiumINACTIVE INGREDIENT7FLD91C86K1
hydrochloric acidINACTIVE INGREDIENTQTT17582CB1
POLYVINYL ALCOHOLINACTIVE INGREDIENT532B59J9901
sodium chlorideINACTIVE INGREDIENT451W47IQ8X1
sodium hydroxideINACTIVE INGREDIENT55X04QC32I1
SODIUM PHOSPHATE, DIBASICINACTIVE INGREDIENTGR686LBA741
waterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21695-18721695-187-05, 21695-187-15
60758-188

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 10 · 588 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBARACHNOID0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRASPINALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION, CONCENTRATE / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / RECTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74CONCENTRATE / ORAL17 mg/5mlExact identifier — unii candidate
14 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ORAL9 mgExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IELIXIR / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSYSTEM / IONTOPHORESIS3.1 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / DENTAL0.4 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / ENDOTRACHEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION/ DROPS / OPHTHALMIC3 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRA-ARTICULAR26 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XENEMA / RECTAL0.7 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR360 mgExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IPASTE / DENTAL0.6 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IFILM / BUCCAL0.09 mgExact identifier — unii candidate
174 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAPLEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / ORAL223 mgExact identifier — unii candidate
148 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XCREAM / TOPICAL0.4 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
POLYVINYL ALCOHOLPOLYVINYL ALCOHOL532B59J990TABLET, EXTENDED RELEASE / ORAL96 mgExact identifier — unii candidate
17 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ITABLET, EXTENDED RELEASE / ORAL13 mgExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRAVESICAL157 mgExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / EPIDURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION / INTRABURSAL0.01 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION / INTRATYMPANIC1 mgExact identifier — unii candidate
148 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION / SUBCUTANEOUS6 mgExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KCONCENTRATE / ORAL20 mgExact identifier — unii candidate
77 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRACARDIAC70 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRAVENOUS1037 mgExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IGEL / OPHTHALMIC6 mgExact identifier — unii candidate
174 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISOLUTION / AURICULAR (OTIC)0.8 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7INJECTION / INTRAMUSCULAR1 mgExact identifier — unii candidate
24 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / EPIDURAL3535 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32ISUSPENSION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / PARENTERAL584 mgExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBTABLET, FILM COATED / ORALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / SUBMUCOSAL17 mgExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SUSPENSION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR27 mgExact identifier — unii candidate
174 equally ranked IID candidates
POLYVINYL ALCOHOLPOLYVINYL ALCOHOL532B59J990SUSPENSION / ORAL5 mgExact identifier — unii candidate
17 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBARACHNOIDADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAPERITONEAL0.54 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / AURICULAR (OTIC)18 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, EMULSION / INTRAVENOUS0.62 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium hydroxideSODIUM HYDROXIDE55X04QC32IGEL, METERED / TRANSDERMAL350 mgExact identifier — unii candidate
174 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVENOUS2916 mgExact identifier — unii candidate
134 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRA-ARTERIAL840 mgExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062452-001GENOPTICGENTAMICIN SULFATEEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1084e616aacf4f…
2026-08-18 06:07:402026-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1031067a03dcf5…
2025-08-23 18:47 UTC2025-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-106a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103f01610625f2…
2019-09-15 20:21 UTC2019-09A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-109b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-103f0d92c62455…
2023-05-13 08:27 UTC2023-05A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMIC1984-10-10053a50430f4f…
2023-01-26 05:58 UTC2023-01A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-103a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062452-001GENOPTICEQ 0.3% BASESOLUTION/DROPS / OPHTHALMICATRS1984-10-10f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062452-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062452-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062452-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062452-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062452-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062452-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062452-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062452-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062452-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062452-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062452-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062452-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062452-001AT1ea99ee380514…
2023-01-26 05:58 UTC2023-01A062452-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062452-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062452-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A062452-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A062452-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
d7a27e38-0553-4d4b-8438-fed235e9b989d7a27e38-0553-4d4b-8438-fed235e9b9892010-09-27Warnings, Adverse reactionsExact identifier
spl id: d7a27e38-0553-4d4b-8438-fed235e9b989
spl set id: d7a27e38-0553-4d4b-8438-fed235e9b989

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.